T cell engagers, including Imdelltra, show promise in small cell lung cancer, outperforming chemotherapy in trials and changing the standard of care. Antibody-drug conjugates like I-DXd and ABBV-706 ...

My cancer story is a bit of a winding tale. Some people are diagnosed with metastatic breast cancer de novo, meaning they didn’t learn of their cancer when it was at an earlier stage, but not me. When ...

FOX 5 Journalist Judayah Murray shares the inspiring story of Joanne Cure, a woman who developed advanced lung cancer despite being a non-smoker. FOX 5’s Kevyn Stewart spoke with Joanne about her ...

Hoschton resident Joanne Cure survived stage 4 lung cancer after being given two years to live. Her treatment included surgery and targeted therapy for an EGFR gene mutation. Now 78, Cure says her ...

If everyone eligible had a lung cancer screening, 62,000 lives would be saved over five years, a new study shows. By Simar Bajaj Tens of thousands of lives could be saved if more people got screened ...

Researchers from UC San Digo have discovered an unusual new way by which cancer cells, illustrated here, can resist treatment and regrow. Photo credit: iStock/wildpixel The emergence of cancer drug ...

STOCKHOLM, Nov 18 (Reuters) - Growth in U.S. markets helped Swedish fintech firm Klarna (KLAR.N), opens new tab to achieve a 26% jump in third-quarter revenue, beating expectations in its first report ...

Immunotherapy post chemoradiotherapy has improved 5-year survival rates in limited-stage SCLC to 40%-50%, a significant increase from past single-digit outcomes. T ...

Roughly a quarter of all cancerous tumors are caused by mutations in the KRAS gene, which fosters cell growth. For more than three decades, scientists believed these mutations were impervious to ...

A new type of cancer cell that "warrants urgent investigation" has been discovered in childhood leukemia and could impact clinical care. Research into new or repurposed treatments that target this new ...

AstraZeneca Plc’s profit rose more than analysts anticipated last quarter, buoyed by demand for its blockbuster cancer and diabetes drugs. Earnings per share, excluding some items, climbed 14% to ...